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Improving, and auditing, access to clinical trial results
All trials should be registered, with their full methods and results reported, and routine audit on the
extent of information withheld
Ben GoldacreWellcome research fellow in epidemiology 1, Carl Heneghan professor 2
1London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; 2Centre for Evidence Based Medicine, Department of Primary Care
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The House of Commons Public Accounts Committee delivered
a remarkable report on 3 January. Its initial remit was the United
Kingdom’s £424m (€510m; $697m) stockpile of oseltamivir
(Tamiflu), but the committee soon broadened out—with evident
surprise—into the ongoing problem of clinical trial results being
routinely and legally withheld from doctors, researchers, and
patients.
This situation has persisted for too long. The first quantitative
evidence on publication bias was published in 1986.1 Iain
Chalmers described in 2006 how progress in the 1990s soon
deteriorated into broken promises.2 Recent years have seen
extensive denial. The Association of the British Pharmaceutical
Industry (ABPI) has claimed that these problems are historic,
and that results are now posted on clinicaltrials.gov. The recently
defunct Ethical Standards in Health and Life Sciences Group,3
which most UK medical and academic professional bodies
signed up to, falsely claimed that a “robust regulatory
framework” ensures access to trial results.4 US legislation
requiring all results to be posted on clinicaltrials.gov within 12
months of completion has been widely ignored,5 with no
enforcement. There has also been covert activity from
industry—a leaked memo on its “advocacy” strategy included
“mobilising patient groups” to campaign against transparency.6
Despite this, we have achieved considerable progress. The
AllTrials.net campaign, started 12 months ago, calls for all trials
on all uses of all currently prescribed treatments to be registered,
with their full methods and results reported.7 It now has the
support of most medical and academic professional bodies as
well as the National Institute for Health and Care Excellence
(NICE), Medical Research Council, Wellcome, more than 130
patient groups, 60 000 members of the public, and many in
industry including GlaxoSmithKline. The Health Research
Authority has announced that registration will be a condition
of ethics committee approval.8 The BMA has passed a motion
stating that withholding trial results is research misconduct,9
and the General Medical Council is re-examining its guidance
on the matter.
There have also been extensive new proposals for greater
transparency from European Union legislators, the European
Medicines Agency (EMA),10 and industry bodies.11All, however,
share the same loophole—they all propose improved access to
information on trials conducted from 2014 onwards. This means
that almost all trials relevant to current medical practice would
be exempt (including, for example, those on oseltamivir).
We now have an unprecedented opportunity for change, with
considerable support from medical and academic professional
bodies, policy makers, patient groups, and—importantly—the
public. It’s time to consider what practical improvements can
be made.
Firstly, by whatever means necessary, the methods and results
of all previous trials must be accessible to the medical and
academic community, which produces the guidelines and
systematic reviews that inform patient care. It is commonly
assumed that it would be difficult to enforce demands for trial
results from diffuse global organisations, but we have never
tried simply asking in an organised fashion. For example, the
EMA could ask all research organisations and companies with
a marketing authorisation for full methods and results of all
trials they have conducted, so that these can be posted online,
on the first ever register of trials that aspires to be a complete
record of all research. If this invitation is declined, we could be
told.
Secondly, while the current state of secrecy continues, there is
much to be done with the most basic research tool in
medicine—audit. Industry is quibbling over the precise
proportion of trials that go undisclosed. This should not be a
matter of debate.We need a trials observatory, covering all trials
on all currently used treatments, that matches registry entries
and other sources of information on completed trials against
sources of results, whether those are in academic papers, clinical
study reports, regulatory documents, or online postings. From
these data we could derive live dashboards on transparency to
drive up best practice, identify the best and worst companies
for missing results, the treatments where most information is
missing, the best and worst investigators, and more.
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This is actionable information. If routine audit shows a particular
principal investigator is performing badly, withmany unreported
results, should ethics committees grant them access to more
trial participants?Will patients participate in trials for companies
that withhold results? If two treatments have equivalent benefits,
but one comes from a company with a track record of
transparency and the other from a company that actively
undermines the transparency campaign, are those two treatments
still equivalent, and which should a cautious clinician prescribe?
One aspect of the committee’s report was missed by popular
commentators, but it exemplifies the peculiarity of the current
situation. Professor Kent Woods, head of the Medicines and
Healthcare Products Regulatory Agency (MHRA), told the
committee that European regulators had everything on
oseltamivir. Evidence from the Cochrane Collaboration shows
that this is not true. Cochrane asked the EMA for all the
documents it held on oseltamivir, under that agency’s contested
new transparency policy, and the agency complied—on several
trials it held incomplete information on the methods and results,
and for many more trials, it held nothing.12 The Public Accounts
Committee expressed concern, and Professor Woods may wish
to clarify this matter. But it is odd that there is any uncertainty
about what evidence exists, or what the MHRA, EMA, and
NICE have seen, on currently prescribed treatments (www.bmj.
com/tamiflu).
It is also remarkable that the medical community needs a
committee of generalist politicians to reflect these problems
back to us. We spend millions on individual trials to exclude
bias and often to detect subtle differences between treatments,
but we let those biases pour back in unnecessarily when we
permit whole trials to be withheld. Future generations may look
back at our present tolerance of withheld trial results in the same
way that we look back on medieval blood letting.
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